NeuroVive and Arbutus sign termination agreement Lund,

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 21, 2016 at 6:45 AM

NeuroVive and Arbutus sign termination agreement

Lund, Sweden, October 21, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the license agreement with Arbutus Biopharma (formerly OnCore Biopharma, Inc.) has been terminated and all rights to the NVP018 compound have been reverted back to NeuroVive. The agreement, signed in 2014, was related to the development and commercialization of NeuroVive’s compound NVP018 for oral treatment of Hepatitis B viral infection. In its portfolio of several Hepatitis B compounds, Arbutus has previously made the decision to proceed with other compounds and to discontinue the development of NVP018 for this indication. As a consequence, the agreement between Arbutus and NeuroVive has now been terminated. Under the termination agreement, NeuroVive will at no cost receive NVP018 drug product and material produced by Arbutus Biopharma, representing a value of approximately 1.5 MUSD. Data from preclinical and CMC development have been transferred. Furthermore, all license rights to the NVP018 compound have been reverted to NeuroVive for further development in any potential indication. “We have appreciated the interactions with Arbutus and there are a number of valuable learnings that have come out of the preclinical development activities. As we see several very exciting potential treatments with NVP018 in areas with unmet medical need, the R&D team is currently exploring various options for further development of these opportunities. The material provided by Arbutus will be most useful in these activities”, said Erik Kinnman, CEO of NeuroVive. About NVP018 NVP018 is a potent non-immunosuppressive cyclophilin inhibitor of the novel compound class Sangamides. NVP018 is the oral version of NeuroVive’s lead compound from its cyclophilin platform and has undergone extensive preclinical development and evaluation in various efficacy models. The drug candidate NVP018 was licensed to a third party in September 2014, Arbutus Biopharma (formerly OnCore Biopharma) for oral treatment of Hepatitis B. About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, drug development and production expertise, as well as commercial partners. NeuroVive has a project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to neurological and metabolic diseases. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or ir.usa@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on October 21, 2016.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Everest Group Faces Shaky Ground in Securities Fraud Suit

Investors Take Aim at Everest Group's Alleged Missteps Looks like Everest Group, Ltd. (NYSE: EG) has found itself knee-deep in legal quicksand. There's a class-action lawsuit afoot, spearheaded by the folks at Schall, Brown & Schwartz LLP. They're putting forward claims that Everest, a player in the securities exchange, was painting a misleading picture when it came to...

Doppel's Strategic Expansion: Adding PropRise Innovators

Doppel Boosts Its Team with PropRise Founders The market doesn’t lie: when a company's on a roll, you watch it closely. Doppel's latest move is a serious signal. They've snagged PropRise, a sprightly Y Combinator graduate, and landed its founders, Jean-Michael Diei and Matthew Krager, right into their engineering fold. These guys aren't greenhorns—cutting their teeth...

Johnsonville's Election Effort: Sausage for Dinner Gains Momentum

Sausage Politics: A Tasty New Agenda Well, ain't that something? A sausage campaign running parallel to the midterms wasn't exactly on my bingo card. But here we are, America, dealing with a 'Sausage Tsunami.' This cheeky strategy from Johnsonville sure packs a punch, leveraging electoral fatigue to put sausage right where they want it: on your dinner plate. The Campaign...

Silvercorp Updates El Domo Budget Amid Challenges

Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...

Historic Surge: Women Veterans Join 120th Congress

The Winds of Change Are Blowing Through Washington It looks like the face of Congress is getting a combat-ready makeover with the latest election results. Veterans are stepping up to the plate, claiming at least 79 seats in the 120th Congress, with a historic presence of women veterans making waves. Yeah, we're talking about 11 women veterans hitting the halls of power,...

Life with PAH: A Journey of Awareness and Hope

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

The Braff Group's 400th Health Care M&A Milestone

No one just stumbles into 400 successful deals without a whole lot of grit, especially in the gnarly jungle of health care services mergers and acquisitions. The Braff Group, a stalwart in this arena since 1998, has just hit this remarkable milestone. If you ask me, this isn't just a number—it's a testament to the blood, sweat, and relentless dedication poured into...

Citius Unveils Promising LYMPHIR Data at EORTC Conference

A Closer Look at LYMPHIR's Impact on CTCL Patients Well, here's a whiff of genuine hope for folks grappling with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Coming out of New Jersey, Citius Oncology has dished out some pretty promising news, fresh from the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group's annual...

Webull Corp Caught in Legal Storm; Investors Take Note

A Legal Storm Brewing It's like walking into a saloon, expecting a smooth drink, only to find a bar fight breaking out in front of you. That's the scene with Webull Corporation (NASDAQ: BULL) right now. This time, they ain't just shooting the breeze; they're in the line of legal fire. SBS Law, a heavyweight in shareholder rights, is rallying the troops for a class action...

NACCO Navigates Strong 2026 Q3, Faces Solar Cost Hurdles

Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...